Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
In the treatment of ischemic symptoms associated with peripheral arterial disease, the use of once-daily SID142 appears to be as good as twice-daily Renexin while having a favourable safety profile, as shown in a phase III study.
Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
23 Apr 2022
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
22 Apr 2022
SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC
Findings from the SPOTLIGHT trial have shown the efficacy of administering durvalumab after chemoradiotherapy (CRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC
21 Apr 2022
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
An observational study from Singapore has shown that the incidence of cerebral venous thrombosis (CVT) following SARS-CoV-2 infection is greater than that following receipt of an mRNA-based SARS-CoV-2 vaccine.
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
20 Apr 2022
US-guided corticosteroid injection relieves symptoms in hip OA
An ultrasound (US)-guided intra-articular hip injection of corticosteroid and local anaesthetic, administered with advice and education, results in a rapid and sustained symptom response for individuals with hip osteoarthritis (OA), a study has shown.